Want to see GB:GDR full AI Analyst Report?
Top Page
Genedrive
(LSE:GDR)
Select Model
Select Model
Rating:49Neutral
Price Target:
1.00 p
▼(-28.57% Downside)
Action:Reiterated
Date:05/15/26
The score is held back primarily by weak financial performance: large ongoing losses, sustained cash burn, and a shrinking equity base despite low debt. Technicals are a partial offset with price trading above major moving averages and generally neutral momentum indicators, while valuation remains constrained by negative earnings and no dividend yield data.
Positive Factors
Recurring consumables revenue
Genedrive’s business model centers on instrument placements plus recurring single-use test cartridges. That installed-base + consumables model creates predictable, high-frequency revenue streams as utilization scales, supporting long-term margin improvement and cash conversion if adoption continues.
Negative Factors
Persistent cash burn
Operating and free cash flow remain deeply negative, implying ongoing reliance on external financing. Persistent cash burn constrains strategic options, risks recurrent dilution or covenant pressure, and reduces the effective runway unless revenue scale or gross margins improve materially.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring consumables revenue
Genedrive’s business model centers on instrument placements plus recurring single-use test cartridges. That installed-base + consumables model creates predictable, high-frequency revenue streams as utilization scales, supporting long-term margin improvement and cash conversion if adoption continues.
Read all positive factors
Genedrive (GDR) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£22.08M
Dividend YieldN/A
Average Volume (3M)4.28M
Price to Earnings (P/E)―
Beta (1Y)-0.78
Revenue Growth65.60%
EPS Growth74.84%
CountryUK
Employees43
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-0.01
Shares Outstanding1,605,568,200
10 Day Avg. Volume4,706,568
30 Day Avg. Volume4,281,453
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)5.40
Price to Sales (P/S)10.17
P/FCF Ratio-1.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Genedrive Business Overview & Revenue Model
Company Description
Genedrive Plc, a molecular diagnostics firm established in Manchester, UK, in 2000 (and known as Epistem Holdings Plc until its name change in July 2016), focuses on developing and commercializing innovative point-of-care diagnostic platforms. The...
How the Company Makes Money
Genedrive makes money primarily through the sale of its molecular diagnostics platform and the associated recurring consumables used to run tests. Key revenue streams typically include: (1) instrument sales or placements of the Genedrive device to...
Genedrive Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
34
Negative
Cash Flow
22
Negative
| Breakdown | TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.07M | 764.00K | 501.00K | 55.00K | 49.00K | 687.00K |
| Gross Profit | 898.00K | 764.00K | 254.00K | -199.00K | -3.82M | -3.82M |
| EBITDA | -5.58M | -5.36M | -7.49M | -5.70M | -5.37M | -1.37M |
| Net Income | -5.34M | -5.23M | -7.08M | -5.15M | -4.67M | -691.00K |
Balance Sheet | ||||||
| Total Assets | 1.75M | 2.81M | 6.80M | 4.51M | 6.62M | 4.88M |
| Cash, Cash Equivalents and Short-Term Investments | 387.00K | 1.18M | 5.19M | 2.60M | 4.59M | 2.57M |
| Total Debt | 500.00K | 0.00 | 19.00K | 241.00K | 16.00K | 119.00K |
| Total Liabilities | 2.17M | 1.38M | 1.44M | 2.47M | 1.01M | 1.28M |
| Stockholders Equity | -415.00K | 1.44M | 5.36M | 2.04M | 5.61M | 3.59M |
Cash Flow | ||||||
| Free Cash Flow | -3.90M | -5.12M | -3.80M | -3.83M | -4.67M | -5.29M |
| Operating Cash Flow | -3.89M | -5.10M | -3.77M | -3.78M | -4.61M | -5.18M |
| Investing Cash Flow | -10.00K | -23.00K | 1.00K | -37.00K | 45.00K | 33.00K |
| Financing Cash Flow | 2.19M | 1.12M | 6.36M | 1.82M | 6.58M | -456.00K |
Genedrive Technical Analysis
Positive
1.40
Price Trends
1.20
Positive
1.16
Positive
1.08
Positive
Market Momentum
0.06
Negative
63.26
Neutral
43.64
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:GDR, the sentiment is Positive. The current price of 1.4 is above the 20-day moving average (MA) of 1.29, above the 50-day MA of 1.20, and above the 200-day MA of 1.08, indicating a bullish trend. The MACD of 0.06 indicates Negative momentum. The RSI at 63.26 is Neutral, neither overbought nor oversold. The STOCH value of 43.64 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:GDR.
Genedrive Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | £1.58B | -10.12 | -35.45% | ― | 14.80% | 16.88% | |
59 Neutral | £108.66M | 53.72 | 3.01% | 4.36% | 2.73% | -65.94% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | £27.17M | -12.80 | -55.91% | ― | 40.37% | -13.70% | |
49 Neutral | £22.08M | -1.26 | -1044.57% | ― | 65.60% | 74.84% | |
45 Neutral | £18.14M | -0.33 | -631.25% | ― | ― | ― | |
40 Underperform | £13.01M | -3.75 | -135.35% | ― | 13.42% | 65.63% |
* Healthcare Sector Average
GB:GDR
Genedrive
1.35
0.93
221.43%
GB:EKF
EKF Diagnostics Holdings
25.25
-5.85
-18.81%
GB:RENX
Renalytix
4.15
-1.70
-29.06%
GB:ABDX
Abingdon Health PLC
10.75
5.00
86.96%
GB:APTA
Aptamer Group Plc
0.38
-0.73
-65.91%
GB:ONT
Oxford Nanopore Technologies PLC
157.50
-13.50
-7.89%
Genedrive Corporate Events
Business Operations and StrategyExecutive/Board Changes
Genedrive strengthens board with Graham Cole CBE as new chair
Positive
Jul 14, 2026
Genedrive plc, the Manchester-headquartered AIM-listed point-of-care pharmacogenetic testing specialist, has appointed Graham Cole CBE as Chair and independent Non-Executive Director with immediate effect, bringing over 40 years of leadership expe...
Business Operations and StrategyExecutive/Board ChangesFinancial DisclosuresPrivate Placements and FinancingRegulatory Filings and Compliance
Genedrive lifts revenues as NHS and international uptake of rapid genetic tests builds
Positive
Jul 13, 2026
Genedrive reported unaudited FY26 income of about £1.4 million, up from roughly £1.0 million in FY25, reflecting growing adoption of its MT-RNR1 and CYP2C19 tests in the UK and abroad, with around one quarter of revenue now generated int...
Business Operations and StrategyProduct-Related Announcements
Genedrive Wins Ministerial Backing as NHS Expands Rapid Pharmacogenetic Testing
Positive
Jul 10, 2026
Genedrive has gained high-profile validation for its MT-RNR1 ID Kit after UK Health Minister Preet Kaur Gill cited rapid pharmacogenetic testing for antibiotic-induced hearing loss in newborns as a powerful, practical example of personalised medic...
Business Operations and StrategyExecutive/Board Changes
Genedrive launches board shake-up as chairman Ian Gilham steps down
Neutral
Jul 1, 2026
Genedrive plc, headquartered in Manchester, develops and commercialises precision pharmacogenetic tests such as the Genedrive CYP2C19 ID Kit for stroke patients and the Genedrive MT-RNR1 ID Kit for newborns, with a focus on embedding UK-developed ...
Business Operations and StrategyProduct-Related Announcements
Genedrive expands CYP2C19 diagnostics with Thermo Fisher lab collaboration
Positive
Jun 29, 2026
Genedrive has signed a collaboration agreement with Thermo Fisher Scientific to develop the Genedrive CYP2C19 HT Kit, a high-throughput pharmacogenetic in vitro diagnostic test for use on Thermo Fisher’s QuantStudio 5 Dx PCR platform, target...
Business Operations and StrategyProduct-Related Announcements
Genedrive’s MT-RNR1 Test Adopted as Routine Neonatal Service at Manchester NHS Trust
Positive
Jun 18, 2026
Genedrive plc said Manchester University NHS Foundation Trust has moved the Genedrive MT-RNR1 ID Kit, which screens newborns for a genetic variant linked to aminoglycoside-induced hearing loss, into business-as-usual clinical service across its th...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and Financing
Genedrive Secures £0.76m R&D Tax Credit to Support Expansion of Point-of-Care Genetics
Positive
Jun 5, 2026
Genedrive plc, a Manchester-headquartered pharmacogenetic diagnostics company focused on point-of-care tests for personalised prescribing, has built a portfolio that includes two CE-IVD approved and NICE-recommended assays deployed in NHS settings...
Business Operations and StrategyRegulatory Filings and Compliance
Genedrive Reports No Change in Share Option Scheme Balances in Latest Block Listing Return
Positive
Jun 1, 2026
Genedrive plc has confirmed its latest six‑monthly block listing return, reporting no changes in the number of securities available under its 2007 Share Option Scheme, 2017 Share Option Scheme and Unapproved Share Option Scheme for the perio...
Regulatory Filings and Compliance
Genedrive Reports No Share Issuance in Latest Block Listing Return
Positive
Jun 1, 2026
Genedrive plc has reported its latest six-monthly block listing return, confirming that no new shares were issued or allotted under its 2007 Share Option Scheme, 2017 Share Option Scheme, or Unapproved Share Option Scheme for the period from 1 Dec...
Business Operations and StrategyExecutive/Board Changes
Genedrive reshapes board as major shareholder joins and long-serving chairman prepares exit
Positive
May 26, 2026
Genedrive has strengthened its governance by appointing major shareholder David Nugent, who holds more than a quarter of the company’s shares and recently acted as a cornerstone investor in its February equity financing, as a non-executive d...
Business Operations and StrategyProduct-Related Announcements
Genedrive Test Adopted as Routine Neonatal Service at Sussex NHS Trust
Positive
May 5, 2026
Genedrive plc said University Hospitals Sussex NHS Foundation Trust has moved its Genedrive MT-RNR1 ID kit for preventing antibiotic-induced hearing loss in neonatal intensive care units to a Business as Usual clinical service from 1 May 2026. The...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.